# What Did Studies Find About These Three Peptides? > Plain Metabolic & Weight Research Peptides — Swe Peptider — Swe Peptider explains studies of three metabolic and weight-research peptides: MOTS-c, semaglutide, and tesamorelin. Plain facts, firm limits, no medical advice. **BODY FUEL AND WEIGHT STUDIES** See what happened in studies of semaglutide, tesamorelin, and MOTS-c. You’ll also see where proof is thin or missing, so one hopeful result doesn’t look final. **WHERE THIS DESK POINTS** Beyond this desk's Tesamorelin evidence ledger, [Promise Peptides](https://mypromise.com/products/tesamorelin) (mypromise.com) runs a prescription peptide care model in which a licensed clinician evaluates each person before making any prescribing decision. ![Promise Peptides Tesamorelin product card with Rx only marking](https://mypromise.com/media/products/tesamorelin.png) *Promise Peptides product image (mypromise.com) — Tesamorelin, marked Rx only.* The card is marked Rx only; a licensed clinician decides whether to prescribe after evaluation. ## What did the main studies find? - Among these three, **semaglutide** has the most proof. Trials with **tens of thousands** of people support approved uses for type 2 diabetes, weight, and heart risk [8][9]. - In one direct trial, tirzepatide caused more weight loss than semaglutide. FDA approval doesn’t mean one drug is best on every measure that matters to you [6]. - **Tesamorelin** has FDA approval for one narrow use. It lowers deep belly fat tied to an HIV-related fat disorder, while other groups still need their own trials [14][15]. - **MOTS-c** hasn’t been tested by giving it to people. The human report only watched dialysis patients, so natural blood levels aren’t the same as a shot [2]. - This site doesn’t sell a product or give a dose. Your doctor is the right person for medical advice and can weigh facts from your own health. ### [MOTS-c](/mots-c) ![MOTS-c research illustration](images/mots-c.webp) Cells and mice gave hopeful results. No finished trial has tested shots of MOTS-c in people, so benefit and harm for you remain unknown. ### [Semaglutide](/semaglutide) ![Semaglutide research illustration](images/semaglutide.webp) Large trials show clear gains for blood sugar, weight, heart health, and kidney health. Tirzepatide, a newer GLP-1 drug, caused more weight loss in one direct trial, so broad proof doesn’t mean best at every task. ### [Tesamorelin](/tesamorelin) ![Tesamorelin research illustration](images/tesamorelin.webp) Trials support one use: lowering deep belly fat from an HIV-related fat disorder. If your health differs, other claims can’t borrow proof from that narrow group. ## What do the studies say first? Large trials found that semaglutide helped blood sugar, weight, heart health, and kidney health. Tesamorelin lowered deep belly fat in people with a certain HIV-related fat disorder. MOTS-c is far less settled. Researchers have studied cells, mice, and natural MOTS-c levels in dialysis patients. No finished trial has tested MOTS-c shots in people. That gap matters if you’re weighing a claim about the compound. These studies ask how the body uses food for fuel and manages weight. MOTS-c, semaglutide, and tesamorelin are peptides, small proteins made from amino acids. Some peptides act like hormones your body already makes. Still, sharing a name doesn’t give all three the same human proof or settle the risks for your own health. Each claim here stays with the people, mice, or cells that were tested. The site gives no dose and can’t replace a doctor who knows you. ## What does “research peptide” tell you? The words “research peptide” often mean a chemical sold only for tests in a lab. Those words don’t show that the chemical has passed large human trials. Semaglutide shows why the label can confuse. A doctor may prescribe an approved medicine, while a lab seller offers a chemical with the same peptide name. The lab chemical isn’t approved medicine for a person to take. It may not pass the same checks for contents, strength, and germs. Ask what was tested, who received it, and how many people took part. One mouse study can’t answer what a 17,000-person heart study can. Mouse work can still guide later studies. It simply cannot tell you yet what will happen in people. ## How much human proof does each peptide have? For human proof, [**semaglutide**](/semaglutide) leads this group. Tens of thousands of people joined trials about type 2 diabetes, weight, and heart risk [8][9]. Semaglutide copies the gut hormone GLP-1, which aids blood sugar and fullness. In one direct test, tirzepatide caused more weight loss than semaglutide [6]. [**Tesamorelin**](/tesamorelin) has FDA approval for one narrow use. It lowers deep belly fat linked to an HIV-related fat disorder [14][15]. Tesamorelin asks the growth gland to send out more of your own growth hormone. Healthy men showed that change, but other claimed uses still lack equal trials [16]. [**MOTS-c**](/mots-c) has mostly cell and mouse work [1][5]. One report followed dialysis patients and measured MOTS-c already in their blood [2]. The dialysis report didn’t give MOTS-c to anyone. What a MOTS-c shot might do, including harm, remains unanswered. In mice, MOTS-c attached to a protein called casein kinase 2, which controls some cell work. The tie helped muscle stay strong and take in sugar, but people haven’t been tested. The [comparison page](/compare) lines up the three sets of studies. You can see which claims rest on people, mice, or cells. ## How can you tell a strong claim from a weak one? First, look at who was studied and how many people took part. A Phase 2 trial is an early human test, often with a few hundred people. The result needs a larger, longer trial before it can count as firm proof. A mouse test likewise answers a question about mice, not your likely result or risk. FDA approval also covers a set use. Tesamorelin’s approval for an HIV-related fat disorder doesn’t prove general weight loss outside that group. Each page names the kind of study and who took part. The source note helps you judge how firm each claim is. --- An independent audit of the metabolic-peptide literature that says plainly what's proven, what's preliminary, and what's still guesswork.